Onflict of interest.Oxygen 2021,
pathogensReviewVancomycin Use in Children and Neonates across
Onflict of interest.Oxygen 2021,
pathogensReviewVancomycin Use in Children and Neonates across Three Decades: A Bibliometric Evaluation with the Top-Cited ArticlesChiara Minotti , Elisa Barbieri , Carlo Giaquinto and Daniele DonDivision of Pediatric Infectious Ailments, Division of Women’s and Children’s Overall health, University of Padova, 35100 Padova, Italy; [email protected] (E.B.); [email protected] (C.G.); [email protected] (D.D.) Correspondence: [email protected]: Vancomycin is regularly prescribed in pediatrics, especially in intensive care unit settings, to treat Gram-positive bacterial infections. This work aims to collect the top-cited Compound 48/80 manufacturer articles of pediatric and infectious diseases places to collect the present evidence and gaps of know-how on the use of vancomycin in these populations. Essentially the most relevant journals reported inside the “pediatrics” and “infectious diseases” categories of the 2019 edition of Journal Citation Reports had been browsed. Articles with more than 30 citations and published during the last three decades have been collected. A bibliometric evaluation was performed and 115 articles were retrieved. They had been published in 21 journals, having a median impact element of 4.six (IQR two.9.4). Sixty-eight of them (59.1 ) belonged to “infectious diseases” journals. By far the most relevant topic was “bloodstream/complicated/invasive infections”, followed by “antibiotic resistance/MRSA treatment”. As for population distribution, 27 articles were on kids only and 27 on neonates, most of which had been from intensive care unit (ICU) settings. The current literature primarily offers with vancomycin as a therapy for extreme infections and antibiotic resistance, especially in neonatal ICU settings. Lately, interest to new dosing techniques within the neonatal and pediatric population has turn into a sensible topic.Citation: Minotti, C.; Barbieri, E.; Giaquinto, C.; Don D. Vancomycin Use in Children and Neonates across 3 Decades: A Bibliometric Evaluation from the Top-Cited Articles. Pathogens 2021, 10, 1343. https:// doi.org/10.3390/pathogens10101343 Academic Editor: Steven L. Zeichner Received: 23 July 2021 Accepted: 29 September 2021 Published: 18 OctoberKeywords: vancomycin; bibliometric evaluation; top-cited articles; pediatric infectious ailments; youngsters; neonates1. Introduction Vancomycin is one of the most frequently prescribed glycopeptides, particularly in children and newborns in intensive care unit (ICU) settings for the treatment of Grampositive bacterial infections by coagulase-negative Staphylococci (CoNS), Enterococci spp, methicillin-resistant Staphylococcus aureus (MRSA), and C. difficile. It FM4-64 Epigenetics inhibits cell wall synthesis by binding for the D-Ala-D-Ala terminal of the peptide chain and has a volume of distribution of 0.four L/kg [1]. There is significant variability in protein binding, that is believed to be up to 50 [2]. Its bactericidal activity is related towards the area beneath the curve (AUC) and minimal inhibitory concentration (MIC) ratio (AUC/MIC ratio), which, as stated within the literature, has to be higher than 400 to guarantee regular efficacy [1]. Serum levels monitoring is recommended, having a target trough concentration aim of 150 /mL for severe infections. According to these pharmacodynamics data, continuous infusion of vancomycin has been proposed for severe infections, guaranteeing greater steady-state concentrations. On the other hand, there is certainly small consensus on picking out the optimal dosing regimen and administration schedule (in.
